Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors

Journal of Clinical Oncology

Volumn 31, Issue 20, 2013, Pages 2619-2626

  Custódio, Gislaine ^a,b   Parise, Guilherme A ^a,c   Filho, Nilton Kiesel ^a,c   Komechen, Heloisa ^a,d   Sabbaga, Cesar C ^a,c   Rosati, Roberto ^a,d   Grisa, Leila ^a,c,d   Parise, Ivy Z S ^a   Pianovski, Mara A D ^b   Fiori, Carmem M C M ^a,e   Ledesma, Jorge A ^a,c   Barbosa, José Renato S ^b   Figueiredo, Francisco R O ^a   Sade, Elis R ^a   Ibañez, Humberto ^a,d   Arram, Sohaila B I ^a,b   Stinghen, Sérvio T ^a,b   Mengarelli, Luciano R ^a,d   Figueiredo, Mirna M O ^b   Carvalho, Danilo C ^a   Avilla, Sylvio G A ^c   Woiski, Thiago D ^a,c,d   Poncio, Lisiane C ^a,d   Lima, Geneci F R ^a,c   Pontarolo, Roberto ^b   Lalli, Enzo ^f,g   Zhou, Yinmei ^h   Zambetti, Gerard P ^h   Ribeiro, Raul C ^h   Figueiredo, Bonald C ^a,b,c,d,h   more..

^a INSTITUTO DE PESQUISA PELÉ PEQUENO PRÍNCIPE   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c Pequeno Principe Hospital   (Brazil)

^d Pequeno Principe Hospital   (Brazil)

^e West Paraná State University and West Union Paraná Studies and Fight Against Cancer   (Brazil)

^f UNIVERSITÉ CÔTE D'AZUR   (France)

^g INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX TUMOR; ARTICLE; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GERMLINE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; PEDIGREE; PREVALENCE; PRIORITY JOURNAL; BRAZIL; CHILD; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; INCIDENCE; METHODOLOGY; MUTATION; PRESCHOOL CHILD; RISK ASSESSMENT; SEX RATIO;

ADRENAL CORTEX NEOPLASMS; BRAZIL; CHILD; CHILD, PRESCHOOL; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PEDIGREE; RISK ASSESSMENT; SEX DISTRIBUTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883867131     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.3711     Document Type: Article

References (31)

1. Ries LAG, Smith MA, Gurney JG, et al: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. http://seer.cancer.gov/publications/childhood/
2. Pianovski MA, Maluf EM, de Carvalho DS, et al: Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatr Blood Cancer 47:56-60, 2006
3. Ribeiro RC, Sandrini F, Figueiredo B, et al: An inherited p53 mutation that contributes in a tissuespecific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 98:9330-9335, 2001
4. Michalkiewicz E, Sandrini R, Figueiredo B, et al: Clinical and outcome characteristics of children with adrenocortical tumors: A report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22:838-845, 2004
5. Figueiredo BC, Sandrini R, Zambetti GP, et al: Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43:91-96, 2006
6. Varley JM, McGown G, Thorncroft M, et al: Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65:995-1006, 1999
7. West AN, Ribeiro RC, Jenkins J, et al: Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Res 66:5056-5062
8. Gonzalez KD, Noltner KA, Buzin CH, et al: Beyond Li Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250-1256, 2009
9. Pinto EM, Ribeiro RC, Figueiredo BC, et al: TP53-Associated pediatric malignancies. Genes Cancer 2:485-490, 2011
10. Latronico AC, Pinto EM, Domenice S, et al: An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 86:4970-4973, 2001
11. Seidinger AL, Mastellaro MJ, Paschoal Fortes F, et al: Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. Cancer 117:2228-2235, 2011
12. Custodio G, Taques GR, Figueiredo BC, et al: Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS One 6:e18015, 2011
13. Instituto Brasileiro de Geografia e Estatística. http://www.ibge.gov.br/home
14. Pinto EM, Billerbeck AE, Villares MC, et al: Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol 48:647-650, 2004
15. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. Hoboken, NJ, Wiley, 2002
16. Birch JM, Heighway J, Teare MD, et al: Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 70:1176-1181, 1994
17. Michalkiewicz EL, Sandrini R, Bugg MF, et al: Clinical characteristics of small functioning adrenocortical tumors in children. Med Pediatr Oncol 28: 175-178, 1997
18. Custódio G, Komechen H, Figueiredo FR, et al: Molecular epidemiology of adrenocortical tumors in southern Brazil. Mol Cell Endocrinol 351:44-51, 2012
19. Zvetkova I, Apedaile A, Ramsahoye B, et al: Global hypomethylation of the genome in XX embryonic stem cells. Nat Genet 37:1274-1279, 2005
20. Wasserman JD, Zambetti GP, Malkin D: Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol 351: 101-110, 2012
21. Villani A, Tabori U, Schiffman J, et al: Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study. Lancet Oncol 12: 559-567, 2011
22. Achatz MI, Hainaut P, Ashton-Prolla P: Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: A case for newborn screening? Lancet Oncol 10:920-925, 2009
23. Birch JM, Alston RD, McNally RJ, et al: Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621-4628, 2001
24. Kleihues P, Schaüble B, zur Hausen A, et al: Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol 150:1-13, 1997
25. Ruijs MW, Verhoef S, Rookus MA, et al: TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: Mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421-428, 2010
26. Torres LF, de Noronha L, Scheffel DL, et al: Choroid plexus tumours: Epidemiologic comparative study of 24 cases [in Portuguese]. Arq Neuropsiquiatr 62:127-130, 2004
27. Palmero EI, Schü ler-Faccini L, Caleffi M, et al: Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 261:21-25, 2008
28. Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283, 2007
29. Schilling FH, Spix C, Berthold F, et al: Neuroblastoma screening at one year of age. N Engl J Med 346:1047-1053, 2002
30. Soderstrom L, Woods WG, Bernstein M, et al: Health and economic benefits of well-designed evaluations: Some lessons from evaluating neuroblastoma screening. J Natl Cancer Inst 97:1118-1124, 2005
31. Grosse SD, Schechter MS, Kulkarni R, et al: Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics 123:407-412, 2009